By | Little Medicine Monster Global ADC Pipeline Status As of December 6, 2023, a total of 1166 ADC pipelines have been developed globally, with 524 pipelines under research and 16 approved drugs (including two TDM-1 biosimilars). The abandonment rate of pipelines is as high as 54% (1166-524-16/1166). Among the 524 pipelines under research, over … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since ADCs first entered clinical trials in the mid-1990s, they have developed into a very successful oncology … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC, Gemtuzumab-ozogamicin (brand name: Mylotarg), was approved for the treatment of CD33-positive acute myeloid … Read more
Antibody-drug conjugates (ADC) have become one of the most sought-after methods for treating cancer patients. Recently, several notable deals have taken place between small biotech companies developing ADCs and large companies looking to enhance their oncology pipelines. The recent Kangfang AK112 incident has brought bispecific antibodies into the spotlight, with some discussing the viability of … Read more
Compiled by: Oncology Information Source: Oncology Information Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies that target specific antigens with cytotoxic small molecule drugs, combining the targeting specificity of antibody drugs with the powerful lethality of cytotoxins. The aim is to overcome the issues of weak cytotoxicity of monoclonal antibodies and the high toxicity … Read more
Since the end of 2019 and the beginning of 2020, I have been looking at ADCs, and I have discussed with many experts in the field, leading to many misunderstandings, and my understanding has been continuously refreshed. Many articles about ADCs exist, but many of them contain misunderstandings. Now, there are more successful and failed … Read more
Antibody-drug conjugates (ADC) are a class of targeted cancer therapies that combine the high specificity of monoclonal antibodies with the potent activity of small molecule cytotoxic drugs to enhance tumor targeting and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs theoretically have higher efficacy due to their ability to release highly active … Read more
Antibody-drug conjugates (ADC) are also known as “biological missiles”. They connect cytotoxic drugs similar to chemotherapy with monoclonal antibodies, consisting of three parts: antibodies, linkers, and payloads (small molecule cytotoxic drugs). This combination achieves the dual advantages of small molecules and antibody drugs, enabling targeted killing of tumors and other diseases. In recent years, global … Read more
Antibody-drug conjugates (ADCs) have become an important treatment method in the field of oncology, offering superior clinical characteristics compared to chemotherapy. However, the application of ADCs still faces two significant challenges. First, there are very few validated payloads with proven mechanisms of action (MoA), which limits the expansion of indications. Approved ADC payloads cover three … Read more
Since 2000, the ADC field has gradually started to be pushed to market, and in recent years, it has emerged rapidly in the field of cancer treatment, leading to intense competition. To differentiate themselves, some companies are beginning to develop ADCs for non-oncology areas. Although the number of related ADCs is extremely limited and most … Read more